This file is part of IDEAS, which uses RePEc data


[ Papers | Articles | Software | Books | Chapters | Authors | Institutions | JEL Classification | NEP reports | Search | New papers by email | Author registration | Rankings | Volunteers | FAQ | Blog | Help! ]

Pharmaceutical Policies in OECD Countries: Reconciling Social and Industrial Goals

Author info | Abstract | Publisher info | Download info | Related research | Statistics
Author Info
S. Jacobzone
Abstract

Regulation of the pharmaceutical sector needs to reconcile private and social objectives. Public intervention pursues multiple goals which relate to both health and industry policy. Many OECD Governments are also heavily involved as buyers of pharmaceuticals in publicly-financed health care systems. This paper describes recent trends in pharmaceutical expenditure and financing in a first chapter. A second chapter discusses the economics of pharmaceutical markets. A third chapter provides a review of national policies and their attempts to balance public and private objectives.

Pharmaceutical expenditure has been rising steadily as a share of GDP since 1970. However, total health expenditure has also risen. As a result, pharmaceutical expenditure has, on average, maintained its share of total health expenditure in the OECD, close to 15 %. Across countries, pharmaceutical expenditure per capita depends on relative incomes but is also influenced by institutional features. The pharmaceutical ...


La régulation du secteur pharmaceutique doit réconcilier des objectifs sociaux et privés. L'intervention publique poursuit des objectifs multiples, relatifs tant à la politique de santé qu'à la politique industrielle. De nombreux gouvernements de l'OCDE sont également profondément engagés en tant qu'acheteurs de médicaments dans des systèmes de santé financés sur fonds publics. Dans un premier chapitre, cette etude décrit des tendances récentes des dépenses pharmaceutiques et du financement. Un second chapitre discute l'économie des marchés du médicament. Un troisième chapitre offre une revue des politiques nationales et de leurs efforts pour équilibrer les objectifs publics et privés.

Les dépenses pharmaceutiques ont vu leur part du PIB s'accroître constamment depuis 1970. Cependant, la part des dépenses de santé s'est aussi accrue. Il en résulte que les dépenses de médicament ont dans l'ensemble maintenu leur part au sein des dépenses de santé, proche de 15 %. Les dépenses de ...

Download Info
To download:

If you experience problems downloading a file, check if you have the proper application to view it first. Information about this may be contained in the File-Format links below. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.

File URL: http://dx.doi.org/10.1787/323807375536
File Format: text/html
File Function:
Download Restriction: no

Publisher Info
Paper provided by OECD, Directorate for Employment, Labour and Social Affairs in its series OECD Labour Market and Social Policy Occasional Papers with number 40.

Download reference. The following formats are available: HTML (with abstract), plain text (with abstract), BibTeX, RIS (EndNote, RefMan, ProCite), ReDIF
Length:
Date of creation: 17 Apr 2000
Date of revision:
Handle: RePEc:oec:elsaaa:40-en

Contact details of provider:
Postal: 2 rue Andre Pascal, 75775 Paris Cedex 16
Email:
Web page: http://www.oecd.org
More information through EDIRC

For technical questions regarding this item, or to correct its listing, contact: ().

Related research
Keywords:

Other versions of this item:

Cited by:
(explanations, Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.)
  1. Vincenzo Atella & Peter R. Noyce & Ellen Schafheutle & Karen Hassell, 2005. "Affordability of Medicines and Patients' Cost Reduction Behaviors: Empirical Evidence Based on SUR Estimates from Italy and the United Kingdom," CEIS Research Paper 71, Tor Vergata University, CEIS. [Downloadable!]
  2. Jean O. Lanjouw, 2005. "Patents, Price Controls, and Access to New Drugs: How Policy Affects Global Market Entry," NBER Working Papers 11321, National Bureau of Economic Research, Inc. [Downloadable!] (restricted)
  3. Auriol, Emmanuelle & Picard, Pierre, 2008. "Government Outsourcing: Public Contracting with Private Monopoly," IDEI Working Papers 382, Institut d'Économie Industrielle (IDEI), Toulouse. [Downloadable!]
    Other versions:
  4. Antonio Cabrales, 2003. "Pharmaceutical Generics, Vertical Product Differentiation, and Public Policy," Working Papers, Research Center on Health and Economics 662, Department of Economics and Business, Universitat Pompeu Fabra. [Downloadable!]
    Other versions:
  5. Frank Windmeijer & Eric de Laat & Rudy Douven & Esther Mot, 2004. "Pharmaceutical promotion and GP prescription behaviour," CPB Discussion Papers 30, CPB Netherlands Bureau for Economic Policy Analysis. [Downloadable!]
    Other versions:
  6. Klaus Desmet & Clara Eugenia García & Praveen Kujal & Félix Lobo, 2003. "Implementing R&D Policies: An Analysis Of Spain’S Pharmaceutical Research Program," Economics Working Papers we035923, Universidad Carlos III, Departamento de Economía. [Downloadable!]
    Other versions:
  7. John Yfantopoulos, 2008. "Pharmaceutical pricing and reimbursement reforms in Greece," The European Journal of Health Economics, Springer, vol. 9(1), pages 87-97, February. [Downloadable!] (restricted)
  8. Gambardella, Alfonso & Orsenigo, Luigi & Pammolli, Fabio, 2000. "Global Competitiveness in Pharmaceuticals: A European Perspective," MPRA Paper 15965, University Library of Munich, Germany. [Downloadable!]
  9. Vincenzo Atella & Franco Peracchi & Domenico Depalo & Claudio Rossetti, 2006. "Drug compliance, co-payment and health outcomes: evidence from a panel of Italian patients," Health Economics, John Wiley & Sons, Ltd., vol. 15(9), pages 875-892. [Downloadable!]
  10. Christel Lane & Jocelyn Probert, 2003. "Globalisation and Its Impact on Competitiveness: the Case of the British and German Pharmaceutical Industry," ESRC Centre for Business Research - Working Papers wp262, ESRC Centre for Business Research. [Downloadable!]
Statistics
Access and download statistics

Did you know? IDEAS also indexes books.

This page was last updated on 2009-11-17.


This information is provided to you by IDEAS at the Department of Economics, College of Liberal Arts and Sciences, University of Connecticut using RePEc data on a server sponsored by the Society for Economic Dynamics.